You are here

  • Home
  • Archive
  • Volume 9, Issue 3
  • SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation

Article metrics

Article menu
XML
Clinical/translational cancer immunotherapy
Original research
SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation

 

Online download statistics by month:

Online download statistics by month: March 2021 to April 2022

AbstractFullPdf
Mar 2021594592304
Apr 2021378378133
May 202123223278
Jun 202120120163
Jul 202117917960
Aug 202116316350
Sep 202114314366
Oct 202119019069
Nov 202123923961
Dec 202113613845
Jan 202213013763
Feb 202211112169
Mar 2022173188103
Apr 202214916070
Total301830611234